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Introduction
Therapeutic Drug Monitoring (TDM) is an evolving tool
used to optimise the administration of antimicrobial
agents; which are well documented to have toxic side
effects [1]. In combination with increasing antimicrobial
resistance and emphasis on cost-efficiency, provision of
the optimal dose of antimicrobial therapy is a very
attractive prospect.
Pharmacokinetic (PK) indices can be used to classify
the efficacy of an antimicrobial agent. Critical illness
may alter a patients PK behaviour [2] and therefore
these patients may require alternative dosing regimens
for optimal management [3].
Objectives
The aim was to evaluate the current use of TDM in Inten-
sive Care Units (ICU’s) across London, focusing on the
availability of results, the range of drugs for which TDM is
offered and presence of critical care specific regimens.
Methods
A 6 part questionnaire was developed, and data collec-
tion was achieved by telephone interviews with Critical
Care Pharmacists at 27 London Hospitals between
February and April 2015.
Results
All hospitals offered TDM, however there were signifi-
cant differences in the application of this tool. TDM
was reported to be available for Gentamicin, Vancomy-
cin and Amikacin at almost all sites (27 units [100%];
26 units [96%] and 19 units [70%] respectively), with the
majority providing onsite TDM.
Gentamicin was universally available within 6 hours (27
units [100%]). Vancomycin and Amikacin were frequently
available within 6 hours (20 units [74%] and 12 units [44%]
respectively). Teicoplanin was available within 6 hours in
5 units [20%] yet took up to 24 hours in 4 units [15%].
For commonly used drugs (Gentamicin, Vancomycin
and Amikacin) most units followed Trust Specific
Guidelines (27 units [100%], 26 units [96%] and 25 units
[93%] respectively), but ICU specific guidelines were
only available in 6 units [23%] for Gentamicin and
7 units [27%] for Amikacin. Vancomycin had ICU speci-
fic guidelines in 19 units [73%].
Conclusions
This initial survey across London demonstrates that
whilst commonly used antimicrobial agents are often
used with TDM to guide therapy, there is still large var-
iation in the range of antimicrobials for which TDM is
available. There was also shown to be discrepancy in the
availability of test results, which may impact on patient
care if potentially toxic or sub-therapeutic levels take
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Figure 1 Number of Intensive Care Units offering TDM for each
Antimicrobial Agent, separated according to onsite availability.
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24 hours to be detected. It was also interesting to note
that critical care specific guidelines were rare, despite
the potential for pharmacokinetic differences in this
patient group.
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Figure 2 Availability of therapeutic Drug Monitoring- time for
results to be accessible according to antimicrobial agent.
Figure 3 Availability of Guidelines for therapeutic Drug
Monitoring. Chart demonstrates ITU and Trust specific
guidelines according to antimicrobial agent.
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